We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+45.18%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.21B
AUM Growth
+$126M
Cap. Flow
-$107M
Cap. Flow %
-8.85%
Top 10 Hldgs %
77.54%
Holding
46
New
4
Increased
3
Reduced
10
Closed
3

Top Buys

Rank Stock Value
1
ZBIO
Zenas BioPharma
ZBIO
+$21.3M
2
TERN
Terns Pharmaceuticals
TERN
+$5.86M
3
CRVS icon
Corvus Pharmaceuticals
CRVS
+$5.38M
4
TRVI icon
Trevi Therapeutics
TRVI
+$4.79M
5
TENX icon
Tenax Therapeutics
TENX
+$755K

Top Sells

Rank Stock Value
1
SLNO
Soleno Therapeutics
SLNO
+$49.1M
2
DYN icon
Dyne Therapeutics
DYN
+$20.7M
3
AVDL
Avadel Pharmaceuticals
AVDL
+$19.6M
4
TARS icon
Tarsus Pharmaceuticals
TARS
+$15.4M
5
COGT icon
Cogent Biosciences
COGT
+$10.9M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SLNO
1
DELISTED
Soleno Therapeutics
SLNO
$318M 26.29%
6,291,851
-1,025,000
-14% -$49.1M
GERN icon
2
Geron
GERN
$930M
$124M 10.23%
27,225,292
– –
HRMY icon
3
Harmony Biosciences
HRMY
$2.07B
$104M 8.63%
2,606,247
– –
VRNA
4
DELISTED
Verona Pharma
VRNA
$102M 8.45%
3,549,758
– –
SVA
5
DELISTED
Sinovac Biotech, Ltd
SVA
$76.3M 6.32%
11,800,000
– –
TERN
6
DELISTED
Terns Pharmaceuticals
TERN
$57.5M 4.76%
6,895,746
+712,754
+12% +$5.86M
TIL icon
7
Instil Bio
TIL
$49.4M
$42M 3.48%
624,339
– –
DYN icon
8
Dyne Therapeutics
DYN
$4.28B
$40M 3.31%
1,114,960
-520,176
-32% -$20.7M
VRDN icon
9
Viridian Therapeutics
VRDN
$2.15B
$38.2M 3.16%
1,678,207
– –
AVDL
10
DELISTED
Avadel Pharmaceuticals
AVDL
$35.2M 2.91%
2,684,109
-1,287,990
-32% -$19.6M
SLN
11
Silence Therapeutics
SLN
$546M
$20.1M 1.66%
1,105,454
– –
ZBIO
12
Zenas BioPharma
ZBIO
$2.04B
$20M 1.66%
+1,183,260
New +$21.3M
ERAS icon
13
Erasca
ERAS
$6.3B
$18.4M 1.53%
6,756,756
– –
OLMA icon
14
Olema Pharmaceuticals
OLMA
$1.01B
$18M 1.49%
1,505,862
-367,842
-20% -$4.7M
ATXS
15
DELISTED
Astria Therapeutics
ATXS
$17.1M 1.41%
1,552,685
-776,342
-33% -$8.63M
TRML
16
DELISTED
Tourmaline Bio
TRML
$15.2M 1.26%
591,882
– –
RZLT icon
17
Rezolute
RZLT
$474M
$13.6M 1.12%
2,797,704
– –
ORIC icon
18
Oric Pharmaceuticals
ORIC
$1.23B
$13.1M 1.08%
1,277,818
+8,142
+0.6% +$80.5K
SERA icon
19
Sera Prognostics
SERA
$79.5M
$12.9M 1.07%
1,650,440
– –
COGT icon
20
Cogent Biosciences
COGT
$6.95B
$12.1M 1%
1,122,471
-1,122,470
-50% -$10.9M
ABEO icon
21
Abeona Therapeutics
ABEO
$343M
$11.6M 0.96%
1,842,751
– –
CMPS
22
Compass Pathways
CMPS
$1.46B
$10.1M 0.84%
1,608,000
– –
CELC icon
23
Celcuity
CELC
$4.02B
$9.1M 0.75%
610,500
– –
DCTH icon
24
Delcath Systems
DCTH
$399M
$9M 0.75%
997,005
-669,741
-40% -$5.82M
CRVS icon
25
Corvus Pharmaceuticals
CRVS
$1.12B
$7.91M 0.65%
+1,497,268
New +$5.38M
1
2

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return
MB
MidFirst Bank Oklahoma City, Oklahoma $1.21B AUM

Vivo Capital's Q3 2024 Portfolio in Review

As of Q3 2024, Vivo Capital held 46 positions worth $1.21B, up 12% from $1.08B the previous quarter. Its ten largest holdings account for 78% of the portfolio.

Vivo Capital withdrew a net $107M in Q3 2024, closing 3 positions and reducing 10 holdings. Its most notable exit was Tarsus Pharmaceuticals, an estimated $15.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Vivo Capital opened a new position in Zenas BioPharma worth $20M.

  • Vivo Capital's largest Q3 2024 buy was Zenas BioPharma: 1,183,260 shares worth $20M.
  • Vivo Capital added most to Terns Pharmaceuticals in Q3 2024, an estimated $5.86M increase.
  • Vivo Capital's biggest Q3 2024 reduction was Soleno Therapeutics, cutting an estimated $49.1M.
  • Vivo Capital fully exited Tarsus Pharmaceuticals in Q3 2024, selling an estimated $15.4M.
  • Vivo Capital's ten largest holdings make up 78% of its $1.21B portfolio in Q3 2024.
  • Vivo Capital opened 4 new positions and closed 3 in Q3 2024.
  • Vivo Capital's portfolio value rose 12% quarter-over-quarter to $1.21B.

Based on Vivo Capital's 13F filing for Q3 2024, filed 13 Nov 2024.